Cargando…
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored either ALK or ROS1 rearrangements. Patients with malignancie...
Autores principales: | Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888601/ https://www.ncbi.nlm.nih.gov/pubmed/35233056 http://dx.doi.org/10.1038/s41698-022-00256-w |
Ejemplares similares
-
Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with
HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ)
adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
por: Jhaveri, K.L., et al.
Publicado: (2021) -
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
por: Flaherty, Keith T., et al.
Publicado: (2020) -
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023) -
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023) -
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
por: Flaherty, Keith T, et al.
Publicado: (2020)